Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long noncoding RNAs (lncRNAs) exert crucial roles in
hepatocellular carcinoma
(
HCC
) progression. LncRNA
EIF3J
-AS1 is recently reported to be highly expressed in
HCC
and correlates with recurrence-free survival. However, the biological function of
EIF3J
-AS1 and its underlying molecular mechanism are unexplored yet. In the current study, we demonstrated that
EIF3J
-AS1 expression was obviously upregulated in
HCC
tissues compared to adjacent noncancerous tissues. Moreover, the elevated levels of
EIF3J
-AS1 was detected in four
HCC
cell lines (HepG2, SMMC-7721, MHCC97H, HCCLM3) compared with the normal hepatic cell line LO2. Notably, the expression of
EIF3J
-AS1 was correlated with prognostic features including tumor size, vascular invasion and tumor stage. TCGA-LIHC data indicated that the upregulated expression of
EIF3J
-AS1 predicted poor prognosis of
HCC
.
EIF3J
-AS1 knockdown remarkably suppressed the proliferation, migration and invasion of
HCC
cells. Mechanistically,
EIF3J
-AS1 inversely regulated miR-122-5p expression via acting as a competing endogenous RNA (ceRNA) in
HCC
cells. Furthermore, catenin delta 2 (CTNND2) was recognized as a novel target of miR-122-5p. CTNND2 restoration partially reversed
EIF3J
-AS1 knockdown-induced inhibitory effects on
HCC
cell proliferation, migration and invasion. Importantly, we found that hypoxia induced
EIF3J
-AS1 and CTNND2 expression, and led to miR-122-5p downregulation in
HCC
cells.
EIF3J
-AS1 knockdown partially abolished hypoxia-induced
HCC
cell proliferation and mobility. In conclusion, our results provide a new insight into the molecular pathogenesis of
HCC
, and
EIF3J
-AS1 may be a potential therapeutic target for
HCC
.
...
PMID:Hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122-5p/CTNND2 axis. 3142 22